Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease
- PMID: 23318480
- DOI: 10.1038/ajg.2012.430
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease
Abstract
Objectives: The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy.
Methods: Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B). An unfavorable Global Pregnancy Outcome (GPO) was considered if pregnancy developed with obstetric complications in the mother and in the newborn.
Results: A total of 187 pregnancies in the group A, 66 pregnancies in the group B, and 318 pregnancies in the non-exposed group were included. The rate of unfavorable GPO was different among the three groups (31.8% in non-exposed group, 21.9% in group A, and 34.8% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). The rate of pregnancy complications was similar among the three groups (27.7% in non-exposed, 20.9% in group A, and 30.3% in group B). The rate of neonatal complications was different among the three groups (23.3% in non-exposed group, 13.9% in group A, and 21.2% in group B), being lower in pregnancies under thiopurines than among non-exposed (P = 0.01). In the multivariate analysis, the treatment with thiopurines (odds ratio = 0.6; 95% confidence interval = 0.4-0.9, P = 0.02) was the only predictor of favorable GPO, whereas maternal age >35 years at conception was the only predictor of unfavorable GPO. The treatment with anti-TNF-α drugs was not associated with an unfavorable GPO.
Conclusion: The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.
Comment in
-
Editorial: Are thiopurines and anti-TNFα agents safe to use in pregnant patients with inflammatory bowel disease?Am J Gastroenterol. 2013 Mar;108(3):441-3. doi: 10.1038/ajg.2012.436. Am J Gastroenterol. 2013. PMID: 23459048
Similar articles
-
Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.Am J Gastroenterol. 2013 Sep;108(9):1426-38. doi: 10.1038/ajg.2013.171. Epub 2013 Jun 11. Am J Gastroenterol. 2013. PMID: 23752881 Review.
-
The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy.J Obstet Gynaecol. 2013 Jan;33(1):1-8. doi: 10.3109/01443615.2012.716106. J Obstet Gynaecol. 2013. PMID: 23259868 Review.
-
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2. Am J Gastroenterol. 2013. PMID: 23032984
-
Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.Gut. 2011 Feb;60(2):198-203. doi: 10.1136/gut.2010.222893. Epub 2010 Nov 29. Gut. 2011. PMID: 21115547
-
Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines.Am J Gastroenterol. 2010 Sep;105(9):2003-8. doi: 10.1038/ajg.2010.138. Epub 2010 Aug 10. Am J Gastroenterol. 2010. PMID: 20700117
Cited by
-
Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.BMC Pregnancy Childbirth. 2024 Apr 8;24(1):251. doi: 10.1186/s12884-024-06443-w. BMC Pregnancy Childbirth. 2024. PMID: 38589784 Free PMC article.
-
The Fundamentals of Inflammatory Bowel Disease Management in Pregnancy: A Practical Review for the Gastroenterologist.J Can Assoc Gastroenterol. 2024 Jan 20;7(1):121-131. doi: 10.1093/jcag/gwad056. eCollection 2024 Feb. J Can Assoc Gastroenterol. 2024. PMID: 38314178 Free PMC article. Review.
-
IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond.J Clin Med. 2023 Sep 25;12(19):6192. doi: 10.3390/jcm12196192. J Clin Med. 2023. PMID: 37834837 Free PMC article. Review.
-
Inflammatory bowel disease in pregnancy and breastfeeding.Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):504-523. doi: 10.1038/s41575-023-00758-3. Epub 2023 Mar 31. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37002407 Review.
-
Pregnancy in Patients with Inflammatory Bowel Diseases-A Literature Review.Life (Basel). 2023 Feb 9;13(2):475. doi: 10.3390/life13020475. Life (Basel). 2023. PMID: 36836832 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical